



**IFMAD**

[www.ifmad.org](http://www.ifmad.org)

# 16<sup>th</sup> INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS

**ROME, 8 - 10 December 2016**

## **Chairmen**

**Siegfried Kasper** (Austria)  
**Allan H. Young** (UK)

**Stuart A. Montgomery** (UK)  
**Eduard Vieta** (Spain)



**Final Programme**



## SCIENTIFIC COMMITTEE

### Chairmen

Siegfried Kasper (Austria) - Stuart Montgomery (United Kingdom) – Eduard Vieta (Spain) – Allan Young (United Kingdom)

### Scientific Advisers

C.A. Altamura (Italy), D. Baldwin (United Kingdom), B. Bandelow (Germany), M. Bauer (Germany), J. Den Boer (The Netherlands), T. Dinan (Ireland), E. Eriksson (Sweden), N. Fineberg (United Kingdom), S.H. Kennedy (Canada), D. Lecic Tosevski (Serbia), A.A. Mathé (Sweden), H.J. Möller (Germany), S. Pallanti (Italy), J. Raboch (Czech Republic), Z. Rihmer (Hungary), A. Serretti (Italy), D.J. Stein (South Africa), T. Svensson (Sweden), D. Winkler (Austria), S. Yamawaki (Japan), J. Zohar (Israel)

## IMPORTANT ADDRESSES



Publi Créations

### Organizing Secretariat:

**PUBLI CRÉATIONS** - 74, Bd d'Italie - 98000 Monte-Carlo - Monaco

Ph. +377 97973555 - Fax +377 97973550

E-mail: [ifmad@publiccreations.com](mailto:ifmad@publiccreations.com) - Website: [www.ifmad/2016/.org](http://www.ifmad/2016/.org)



### Congress Venue:

**NH Hotel** - Corso Italia 1 – Rome - Italy

Tel: +39 06 84951





## WELCOME LETTER

Dear Colleagues, dear Friends,

It is with a great pleasure that we welcome you to the **16th International Forum on Mood and Anxiety Disorders (IFMAD 2016)** in Rome, one of the most beautiful cities in the world!

IFMAD has a tradition of inviting expert speakers with subjects which provide new insights in treatment of various psychiatric disorders. The meeting always takes place in a collegiate setting which allows for an open interaction between speakers and other experts present with the registrants both in the meeting room and in the intervals.

This year there are substantial sessions on bipolar disorder with a focus on cognitive impairment with a critical analysis of the design issues and the difficult issue of how to treat cognitive problems in bipolar disorder. The place of talking therapies in treating bipolar disorder and how to stage bipolar disorder will also be reviewed as well as the controversial place of antidepressants in bipolar depression.

It is accredited for continuing medical education and to avoid bias, our educational program is completely independent from pharmaceutical support.

We are glad to have you chosen to join us again and share your knowledge with your colleagues in a friendly learning environment

The IFMAD Chairmen



Siegfried Kasper



Stuart A. Montgomery



Allan H. Young



Eduard Vieta

[www.ifmad.org](http://www.ifmad.org)



## ACKNOWLEDGEMENTS

*The Organizing Committee express their gratitude  
in supporting the poster presenters*



*to*



*and*



**Pierre Fabre**

*for their contribution to the Congress*



## SCIENTIFIC PROGRAM - Thursday, 08 DECEMBER 2016

### 15.00 – 16.10 S01 STANDARDS OF CARE FOR OBSESSIVE-COMPULSIVE DISORDER

Chairs: S. Montgomery (UK) – L. Mandelli (Italy)

#### 15.00 – 15.25 S 0101 New Findings from an International Collaboration of Experts

**Naomi Fineberg (UK)**

*Discussion 10 minutes*

#### 15.35 – 16.00 S 0102 How should we treat resistant OCD?

**Stefano Pallanti (Italy)**

*Discussion 10 minutes*

### 16.15 – 18.00 S02 – COGNITION IN BIPOLAR DISORDER

Chairs: N. Fineberg (UK) – S. Montgomery (UK)

#### 16.15 – 16.40 S 0201 Morbidity of cognition in bipolar depression. Unmet need and design issues

**Eduard Vieta (Spain)**

*Discussion 10 minutes*

#### 16.50 – 17.15 S 0202 The treatment of cognitive problems in bipolar disorders

**Allan Young (UK)**

*Discussion 10 minutes*

#### 17.25 – 17.45 S 0203 The place of talking therapies in bipolar disorder

**Sameer Jauhar (UK)**

*Discussion 10 minutes*

### 18.00–19.00 OPENING RECEPTION



## SCIENTIFIC PROGRAM - Friday, 09 DECEMBER 2016

- 08.30 – 10.30**      **S03 - Update on treatment resistant depression**  
 Chairs: S. Kasper (Austria) – D. Winkler (Austria)
- 08.30 – 08.50**      **S 0301 Update on the most advanced pharmacogenetic techniques**  
**Chiara Fabbri (Italy)**  
*Discussion 10 minutes*
- 09.00 – 09.20**      **S 0302 10 easy and effective suggestions to improve antidepressant effects**  
**Laura Mandelli (Italy)**  
*Discussion 10 minutes*
- 09.30 – 09.50**      **S 0303 How to save time: Criteria for the choice of the best antidepressant**  
**Stefano Porcelli (Italy)**  
*Discussion 10 minutes*
- 10.00 – 10.20**      **S 0304 Evidence based treatment algorithm for TRD**  
**Daniel Souery (Belgium)**  
*Discussion 10 minutes*
- 10.30–11.00**      **COFFEE BREAK**
- 11.00 – 12.15**      **S04 – REALLY RAPID RESPONSE ANTIDEPRESSANTS**  
 Chairs: A. Young (UK) – S. Porcelli (Italy)
- 11.00 – 11.25**      **S 0401 Onset of action of serotonin reuptake inhibitors: how slow or rapid is it?**  
**Elias Eriksson (Sweden)**  
*Discussion 10 minutes*
- 11.35 – 12.00**      **S 0402 Placebo controlled evidence of really rapid response in MDD**  
**Siegfried Kasper (Austria)**



*Discussion 15 minutes*

## SCIENTIFIC PROGRAM - Friday, 09 DECEMBER 2016

### 12:15–13:00 INDUSTRY SPONSORED LECTURE

### 13.00–14.30 LUNCH

### 14.30 – 15.00 S05 – ZIKA VIRUS DISEASE AND CNS CONSEQUENCES

Chairs: S. Pallanti (Italy)

#### 14.30 – 14.55 S 0501 Zika virus disease and CNS consequences

Fabrizio Pregliasco (Italy)

*Discussion 5 minutes*

### 15.00 – 15.30 S06 – NUTRITION AND DEPRESSION

Chair: A. Young (UK)

#### 15.00 – 15.25 S 0602 The role of nutrition in managing depression

Ted Dinan (Ireland)

*Discussion 05 minutes*

### 15.30 – 16.00 CU01 – CLINICAL UPDATE 1 - SURVEY

Chairs: S. Kasper (Austria) – S. Montgomery (UK) – A Young (UK)

### 16.00–16.30 COFFEE BREAK



## SCIENTIFIC PROGRAM - Friday, 09 DECEMBER 2016

- 16.30 – 18.15**      **S07 – New thoughts on treatment of anxiety disorders**
- Chairs: E. Eriksson (Sweden) – F. Drago (Italy)
- 16.30 – 16.55**      **S 0701 New treatments and strategies in anxiety disorders**
- Borwin Bandelow (Germany)**
- Discussion 10 minutes*
- 17.05 – 17.30**      **S 0702 The problems of treating anxiety disorders with substantial**
- David Baldwin (UK)**
- Discussion 10 minutes*
- 17.40 – 18.05**      **S 0703 Pain and depression and anxiety**
- Robert Peveler (UK)**
- Discussion 10 minutes*





## SCIENTIFIC PROGRAM - Saturday, 10 DECEMBER 2016

### 09.00–10.00 STROLLING POSTER SESSION

#### 10.00 – 11.00 S08 – NEW INSIGHTS IN THE TREATMENT OF DEPRESSION

Chairs: S. Montgomery (UK) – T. Dinan (Ireland)

##### 10.00 – 10.25 S 0801 Regulatory issues with treatments in depression and anxiety

**Filippo Drago (Italy)**

*Discussion 10 minutes*

##### 10.35 – 11.00 S 08 02 New steps in personalized treatment of depression

**Alessandro Serretti (Italy)**

*Discussion 10 minutes*

#### 11.15 – 12.25 S09 – ADVANCE IN BIPOLAR DISORDER

Chairs: E. Vieta (Spain) – A. Serretti (Italy)

##### 11.15 – 11.40 S 0901 Staging Bipolar Disorder

**Iria Grande (Spain)**

*Discussion 10 minutes*

##### 11.50 – 12.15 S 0902 Antidepressants in bipolar depression

**Andrea Murru (Spain)**

*Discussion 10 minutes*

### 12.25 – 12.30 CLOSING REMARKS FAREWELL COFFEE AND POSTER AWARDS



## Industry Sponsored Lecture – Friday, 09 December 2016

*DISCLAIMER: THE FOLLOWING LECTURE IS ORGANIZED BY INDUSTRY. YOU CANNOT CLAIM CME CREDITS FOR ATTENDING THIS SESSION*

### 12.15–13.00 SPONSORED LECTURE

Chair: S. Kasper (Austria)

#### **What's new for smoking cessation treatments in patients with a psychiatric history?**

**Avi Weizman (Israel)**

*This lecture is organized and funded by Pfizer (and it is intended for Healthcare Professionals only)*





## POSTERS

### **P 01. Suicide and other causes of death among elderly patients with dementia**

Ji Hyun An; Jin Pyo Hong

<sup>1</sup>*Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea*

### **P 02. Anxiety or agitation in mood disorder with mixed features: A review with a focus on validity as a dimensional criterion**

Won-Myong Bahk<sup>1</sup>; Hye-Jin Seo<sup>1</sup>; In Hee Shim<sup>2</sup>; Young-Joon Kwon<sup>3</sup>; Mood-Doo Kim<sup>4</sup>; Kyung Joon Min<sup>5</sup>; Bo-Hyun Yoon<sup>6</sup>; Kwang Heun Lee<sup>7</sup>; Sang-Yeol Lee<sup>8</sup>; Duk-In Jon<sup>9</sup>

<sup>1</sup>*Yeouido St. Mary's Hospital, Seoul, South Korea*; <sup>2</sup>*Cancer Center, Dongnam Institute of Radiological and Medical Sciences, Busan, South Korea*; <sup>3</sup>*Soonchunhyang University, Cheonan, South Korea*; <sup>4</sup>*Jeju National University, Jeju, South Korea*; <sup>5</sup>*Chung-Ang University, Seoul, South Korea*; <sup>6</sup>*Naju National Hospital, Naju, South Korea*; <sup>7</sup>*Dongguk University, Gyeongju, South Korea*; <sup>8</sup>*Wonkwang University School of Medicine, Iksan, South Korea*; <sup>9</sup>*Sacred Heart Hospital, Hallym University, Anyang, South Korea*.

### **P 03. Predictors of a shorter time to recurrence in patients with bipolar disorder: Medication during the acute and maintenance phases and other clinical factors**

Won-Myong Bahk<sup>1</sup>; In Hee Shim<sup>2</sup>; Young-Joon Kwon<sup>3</sup>; Moon-Doo Kim<sup>4</sup>; Bo-Hyun Yoon<sup>5</sup>; Duk-In Jon<sup>6</sup>; Inki Sohn<sup>7</sup>

<sup>1</sup>*Yeouido St. Mary's Hospital, Seoul, South Korea*; <sup>2</sup>*Cancer Center, Dongnam Institute of Radiological and Medical Sciences, Busan, South Korea*; <sup>3</sup>*Soonchunhyang University, Cheonan, South Korea*; <sup>4</sup>*Jeju National University, Jeju, South Korea*; <sup>5</sup>*Naju National Hospital, Naju, South Korea*; <sup>6</sup>*Sacred Heart Hospital, Hallym University, Anyang, South Korea*; <sup>7</sup>*Keyo Hospital, Keyo Medical Foundation, Uiwang, South Korea*

### **P 04. Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review**

Won-Myong Bahk<sup>2</sup>; Kyung Joon Min<sup>1</sup>; Young Sup Woo<sup>2</sup>; Hye-Jin Seo<sup>2</sup>; Kwang Heun Lee<sup>3</sup>; Sang-Yeol Lee<sup>4</sup>; Duk-In Jon<sup>5</sup>; Inki Sohn<sup>6</sup>; RS McIntyre<sup>7</sup>

<sup>1</sup>*Chung-Ang University, Seoul, South Korea*; <sup>2</sup>*Yeouido St. Mary's Hospital, Seoul, South Korea*; <sup>3</sup>*Dongguk University, Gyeongju, South Korea*; <sup>4</sup>*Wonkwang University School of Medicine, Iksan, South Korea*; <sup>5</sup>*Sacred Heart Hospital, Hallym University, Anyang, South Korea*; <sup>6</sup>*Keyo Hospital, Keyo Medical Foundation, Uiwang, South Korea*; <sup>7</sup>*University Health Network, Toronto, Canada*

### **P 05. BDNF in the prediction of response to acute antidepressant treatment in depressive patients.**

Martin Bares<sup>1,2</sup>; Tomas Novak<sup>1,2</sup>; Martin Brunovsky<sup>1,2</sup>

<sup>1</sup>*National Institute of Mental Health, Klecany, Czech Rep.*; <sup>2</sup>*Department of Psychiatry and Medical Psychology, Third Medical Faculty, Charles University, Prague, Czech Rep.*



## POSTERS

### **P 06. Mental Disorders in the elderly based on the International Classification of Functioning, Disability and Health (MentDis\_ICF65+)**

Eleonora Berretti; Rosangela Caruso; Silvia Costa; Sara Massarenti; Maria Giulia Nanni; Luigi Grassi

*Institute of Psychiatry, Department of Biomedical and Surgical Science, University of Ferrara, Ferrara, Italy*

### **P 07. Relationship between director leadership of community mental health center and organizational effectiveness in Korea**

Myungsun Cho<sup>1</sup>; Duk-In Jon<sup>2</sup>; Narei Hong<sup>2</sup>; Myung Hun Jung<sup>2</sup>

<sup>1</sup>Anyang City Mental Health Center, Anyang, South Korea; <sup>2</sup>Hallym University Sacred Heart Hospital, Anyang, South Korea

### **P 08. Religiosity on stable patients with schizophrenia is associated with empathic perspective taking variations**

Rosó Duñó<sup>1</sup>; Joan Carles Oliva<sup>2</sup>; Javier Labad<sup>1</sup>; Diego Palao<sup>1</sup>; Adolf Tobeña<sup>3</sup>

<sup>1</sup>Hospital Universitari Parc Taulí, Servei de Psiquiatria. Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain; <sup>2</sup>Unitat d'Estadística i Avaluació. Fundació Parc Taulí. Hospital Universitari Parc Taulí. Universitat Autònoma de Barcelona., Sabadell, Barcelona, Spain; <sup>3</sup>Department de Psiquiatria i Medicina Forense. Institut de Neurociències. Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain

### **P 09. Modulating effects of chronic vitamin D3 hormone administration on depression-like behavior in the adult female rats after long-term ovariectomy**

Julia Fedotova<sup>1,2,3</sup>; Svetlana Pivina<sup>1</sup>; Anastasia Sushko<sup>1,2</sup>; Tatayna Dudnichenko<sup>4</sup>

<sup>1</sup>I.P. Pavlov Institute of Physiology RASci, St. Petersburg, Russian Federation; <sup>2</sup>ITMO University, St. Petersburg, Russian Federation; <sup>3</sup>I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry RASci, St. Petersburg, Russian Federation; <sup>4</sup>North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, Russian Federation

### **P 10. The effect of a nurse-assisted depression support group**

Masami Hasegawa; Koji Tanaka; Yutaka Nagayama; Yuko Fukasawa

<sup>1</sup>Kanazawa Medical University, Kahoku-gun, Japan

### **P 11. Side effects breaking the blind does not explain the antidepressant effects of the selective serotonin reuptake inhibitors paroxetine and citalopram**

Fredrik Hieronymus<sup>1</sup>; Alexander Lisinski<sup>1</sup>; Staffan Nilsson<sup>2</sup>; Elias Eriksson<sup>1</sup>

<sup>1</sup>University of Gothenburg, Gothenburg, Sweden; <sup>2</sup>Chalmers University of Technology, Gothenburg, Sweden

### **P 12. A Development and Validation of the Korean Personality Rating Scale for Children into Korean Sign Language (KPRC-KSL)**

Dawon Jeong; Soontaeg Hwang; Hyeseon Jo; Sohee Lim

*Department of Psychology, Chungbuk National University, Cheongju, South Korea*





## POSTERS

### **P 13. A study for Development of the Beck Hopelessness Scale**

Hyejeong Jeong; Soontaeg Hwang; Hyeeseon Jo; MinCheol Shin

*Department of Psychology, Chungbuk National University, CheongJu, South Korea*

### **P 14. A study of Emotional Characteristics for Korean Deaf persons: Focused on the Korean Sign Language Versions of the Korean Beck Depression inventory-II (K-BDI-II), Beck Anxiety Inventory(K-BAI), and Hopelessness Scale(K-BHS)**

Hyejeong Jeong; Soontaeg Hwang; Hyeeseon Jo; Mincheol Shin

*Department of Psychology, Chungbuk National University, ChungJu, South Korea*

### **P 15. Outcome of depressive and anxiety disorders among young adults in Finland**

Teija Kasteenpohja<sup>1,2</sup>; Mauri Marttunen<sup>1,3</sup>; Terhi Aalto-Setälä<sup>4</sup>; Jonna Perälä<sup>1,5</sup>; Samuli Saarni<sup>1,6</sup>; Jaana Suvisaari<sup>1,7</sup>

<sup>1</sup>Department Health, Mental Health Unit, National Institute for Health and Welfare, Helsinki, Finland; <sup>2</sup>The Doctoral Program in Clinical Research, Faculty of Medicine, University of Helsinki, Helsinki, Finland; <sup>3</sup>Adolescent Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; <sup>4</sup>The Social Insurance Institute, Helsinki, Finland; <sup>5</sup>Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; <sup>6</sup>Turku University Hospital and University of Turku, Turku, Finland; <sup>7</sup>Department of Social Psychiatry, School of Public Health, University of Tampere, Tampere, Finland

### **P 16. Stigmatization of mental illness**

Marietta Kékes Szabó

*University of Szeged, Szeged, Hungary*

### **P 17. Differences between adolescent and adult suicide attempts in emergency department**

Min Hyuk Kim; Yeon Sik Bang; Seongho Min; Joung Sook Ahn

*Department of Psychiaatry, Yonsei University Wonju College of Medicine, Wonju, South Korea*

### **P 18. Factors affecting suicidal ideation in Korean adolescents**

Moon Doo Kim<sup>1</sup>; Kwang Heun Lee<sup>2</sup>

<sup>1</sup>Jeju National University Hospital, Jeju, Korea, South; <sup>2</sup>College of Medicine, Dongguk University, Gyeongju, South Korea

### **P 19. Reducing Patient Dependence on Benzodiazepines during Outpatient Treatment of Anxiety Disorders**

Joy Kwakuyi; Janet McMillan

<sup>1</sup>University of South Alabama, College of Nursing, Mobile, AL, USA

### **P 20. Depressive Symptom Profiles Indicating the Positive for Depression in Patients with Chronic Physical Diseases**

Young-Joon Kwon

*Soonchunhyang Univ. Hospital, Chun-an, South Korea*



## POSTERS

### **P 21. The relationship between total sleep time and suicidal ideation among elderly in Korea**

Hyochul Lee; Jinpyo Hong; Woojae Myung; Jihui Choe  
Samsung medical center, Seoul, South Korea

### **P 22. The protective effects of hypomanic symptoms in a major depressive episode on suicide attempt in bipolar disorder**

Jongha Lee; Taehyon Ha  
Department of Psychiatry, Seoul National University Bundang Hospital, Kyeonggi, South Korea

### **P 23. The epidemiologic survey of depression and suicidality among North Korean defectors in South Korea**

Kyoungeun Lee; Haesoo Kim; Jin Pyo Hong  
Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul, South Korea

### **P 24. Use of a smartphone application to screen for depression and suicide in Korean general population**

Sangyeol Lee<sup>1</sup>; Bo-Hyun Yoon<sup>2</sup>; Moon-Doo Kim<sup>3</sup>; Won-Myung Bank<sup>4</sup>  
<sup>1</sup>Department of Psychiatry, Wonkwang University School of Medicine, Iksan, South Korea; <sup>2</sup>Department of Psychiatry, Naju National Hospital, Naju, South Korea; <sup>3</sup>Department of Psychiatry, College of Medicine, Jeju National University, Jeju, South Korea; <sup>4</sup>Department of Psychiatry, Yeouido St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea

### **P 25. The effects of an online imagery-based treatment program in patient with workplace-related posttraumatic stress disorder**

Wonjoon Lee; Soo-Hee Choi; Do-Hyung Kang  
Seoul National University Hospital, Seoul, South Korea

### **P 26. Study 329 suggests paroxetine to exert an antidepressant effect in children and adolescents**

Alexander Lisinski; Fredrik Hieronymus; Elias Eriksson  
Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden

### **P 27. The changes of prescribing patterns for inpatients with major depressive disorder**

Kyung Joon Min; Doug Hyun Han  
Chung-Ang University Hospital, Seoul, South Korea



## POSTERS

### **P 28. Synergism between mGluR5 and COX-2 in antidepressant-like action is associated with the alterations in NMDA receptors**

Paulina Misztak<sup>1,2</sup>; Magdalena Sowa-Kućma<sup>1</sup>; Patrycja Pańczyszyn-Trzewik<sup>1</sup>; Szymon Rzeźniczek<sup>1</sup>; Gabriel Nowak<sup>1,2</sup>; Andrzej Pilc<sup>1</sup>; Katarzyna Stachowicz<sup>1</sup>

<sup>1</sup>Department of Neurobiology, Institute of Pharmacology, Polish Academy of Science, Krakow, Poland; <sup>2</sup>Department of Pharmacobiology, Jagiellonian University Medical College, Krakow, Poland

### **P 29. [95] A retrospective population based study into self-harm rates within NHS Greater Glasgow and Clyde during the 2014 Commonwealth Games and Scottish Independence Referendum**

Mathew Morrison; Sophie Flood

NHS Greater Glasgow and Clyde, Glasgow, United Kingdom

### **P 30. Course of depression in patients with different baseline levels of functioning and influence of adherence**

Diego Novick<sup>1</sup>; William Montgomery<sup>2</sup>; Maria Victoria Moneta<sup>3</sup>; Roberto Brugnoli<sup>4</sup>; Hector Dueñas<sup>5</sup>; Josep Maria Haro<sup>3</sup>

<sup>1</sup>Lilly Research Centre, Eli Lilly and Company Limited, Windlesham, United Kingdom; <sup>2</sup>Eli Lilly Australia Pty Ltd, Sydney, Australia; <sup>3</sup>Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain; <sup>4</sup>School of Medicine, Sapienza University, Rome, Italy; <sup>5</sup>Eli Lilly de Mexico, Mexico City, Mexico

### **P 31. Mitochondrial respiration in bipolar affective disorder**

Jiri Raboch<sup>1</sup>; Jana Hroudová<sup>1</sup>; Ekaterina Sigitova<sup>1</sup>; Hana Hansíková<sup>2</sup>; Zdeněk Fišar<sup>1</sup>; Lucie Kalisova<sup>1</sup>; Eva Kitzlerova<sup>1</sup>; Martina Zvěřová<sup>1</sup>

<sup>1</sup>Psychiatric Department, Charles University, 1<sup>st</sup> Faculty of medicine, Prague, Czech Rep.; <sup>2</sup>Department of Pediatrics, Charles University, 1<sup>st</sup> Faculty of Medicine, Prague, Czech Rep.

### **P 32. Factors related to suicidal behavior in patients with bipolar disorder: the effect of mixed features on suicidality**

Hye-Jin Seo<sup>1</sup>; Jeong Seok Seo<sup>2</sup>; Kyung Joon Min<sup>3</sup>; Sang-Yeol Lee<sup>4</sup>; Won-Myong Bahk<sup>1</sup>

<sup>1</sup>Yeouido St. Mary's Hospital, Seoul, South Korea; <sup>2</sup>Konkuk University, Chungju, South Korea; <sup>3</sup>Chung-Ang University, Seoul, South Korea; <sup>4</sup>Wonkwang University School of Medicine, Iksan, South Korea

### **P 33. Effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder**

Hye-Jin Seo<sup>1</sup>; Bo-Hyun Yoon<sup>2</sup>; Young Sup Woo<sup>1</sup>; Won-Myong Bahk<sup>1</sup>; Won Kim<sup>3</sup>; Jeong Seok Seo<sup>4</sup>; Kwang hun Lee<sup>5</sup>; Moon-Doo Kim<sup>6</sup>; Young-Joon Kwon<sup>7</sup>

<sup>1</sup>Yeouido St. Mary's Hospital, Seoul, South Korea; <sup>2</sup>Naju National Hospital, Naju, South Korea; <sup>3</sup>Haeundae Paik Hospital, Seoul, South Korea; <sup>4</sup>Konkuk University, Chungju, South Korea; <sup>5</sup>Dongguk University, Gyeongju, South Korea; <sup>6</sup>Jeju National University, Jeju, South Korea; <sup>7</sup>Soonchunhuang University, Cheonan, South Korea



## POSTERS

### **P 34. Korean Medication Algorithm for Depressive Disorder 2017(I) : Major Depressive Disorder without Psychotic Features**

Jeong Seok Seo<sup>1</sup>; Young Sup Woo<sup>2</sup>; Inki Sohn<sup>3</sup>; Duk-In Jon<sup>4</sup>; Kyung Joon Min<sup>5</sup>; Won-Myoung Bahk<sup>2</sup>

<sup>1</sup>*Konkuk University Chung-Ju Hospital, Chung-Ju, South Korea*; <sup>2</sup>*Catholic University St. Mary's Hospital, SEOUL, South Korea*; <sup>3</sup>*Keyo Hospital, UIWANG-si, South Korea*; <sup>4</sup>*Hallym University Sacred Heart Hospital, ANYANG, South Korea*; <sup>5</sup>*CHUNG-ANG University Hospital, SEOUL, South Korea*

### **P 35. The validity and clinical utility of bipolar questionnaires for screening bipolar disorder with alcohol use disorder : a preliminary study**

Inki Sohn<sup>1</sup>; Jeongseok Seo<sup>2</sup>; Sohyun Park<sup>1</sup>

<sup>1</sup>*Keyo Hospital, Uiwang, South Korea*; <sup>2</sup>*Konkuk University, Chungju, South Korea*; *South Korea*

### **P 36. The role of MeCP2 transcription factor in the pathophysiology and treatment of depression**

Magdalena Sowa-Kucma<sup>1</sup>; Paulina Misztak<sup>1,2</sup>; Patrycja Panczyszyn-Trzewik<sup>1</sup>; Mariusz Papp<sup>1</sup>; Piotr Gruca<sup>1</sup>; Bernadeta Szewczyk<sup>1</sup>; Gabriel Nowak<sup>1</sup>

<sup>1</sup>*Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland*; <sup>2</sup>*Department of Pharmacobiology, Jagiellonian University Medical College, Krakow, Poland*

### **P 37. Behavioral consequences of chronic co-administration of mGluR5 antagonist (MTEP), and COX-2 inhibitor (NS398)**

Katarzyna Stachowicz<sup>1</sup>; Magdalena Sowa-Kućma<sup>1</sup>; Paulina Misztak<sup>1,2</sup>; Patrycja Pańczyszyn-Trzewik<sup>1</sup>; Bernadeta Szewczyk<sup>1</sup>; Gabriel Nowak<sup>1</sup>; Andrzej Pilc<sup>1</sup>

<sup>1</sup>*Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland*; <sup>2</sup>*Department of Pharmacobiology, Jagiellonian University Medical College, Krakow, Poland*

### **P 38. The whole-body cryotherapy as an adjuvant treatment for people who are diagnosed with depressive disorder**

Bartłomiej Stańczykiewicz<sup>1</sup>; Katarzyna Urbańska<sup>1</sup>; Jakub Ubysz<sup>1</sup>; Sylwia Płaczowska<sup>2</sup>; Lilla Pawlik-Sobecka<sup>3</sup>; Izabela Kokot<sup>3</sup>; Dorota Szcześniak<sup>1</sup>; Joanna Rymaszewska<sup>4</sup>

<sup>1</sup>*Division of Consultation Psychiatry and Neuroscience, Department of Psychiatry, Wrocław Medical University, Wrocław, Poland*; <sup>2</sup>*Diagnostics Laboratory for Teaching and Research, Wrocław Medical University, Wrocław, Poland*; <sup>3</sup>*Department of Professional Training in Clinical Chemistry, Wrocław Medical University, Wrocław, Poland*; <sup>4</sup>*Department of Psychiatry, Wrocław Medical University, Wrocław, Poland*





## POSTERS

### **P 39. A Clinical Impression on Efficacy, Tolerability, and Safety of Duloxetine in Depression Patients, from the Application on 100 Patients**

Hiroshi Terada

*Aoi Clinic, Shizuoka, Japan*

### **P 40. Effect of desvenlafaxine on inflammation in recent onset major depression**

Smadar Valérie Tourjman<sup>1</sup>; Emmanuel Stip<sup>2</sup>; Glenda McQueen<sup>3</sup>; Stéphane Potvin<sup>1</sup>; Miriam Beauchamp<sup>4</sup>; Edouard Kouassi<sup>5</sup>

<sup>1</sup>Department of psychiatry, Faculty of Medicine, University of Montréal, Institut Universitaire en Santé Mentale de Montréal, Montréal, Canada; <sup>2</sup>Department of Psychiatry, Faculty of Medicine, University of Montreal, Montreal, Canada; <sup>3</sup>Department of Psychiatry, Faculty of Medicine, University of Calgary, Calgary, Canada; <sup>4</sup>Department of Psychology, University of Montreal, Montreal, Canada; <sup>5</sup>Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Canada

### **P 41. Are inflammation and cognition related in major depression? Inadvertent selection for a cognitively unimpaired subgroup**

Smadar Valérie Tourjman<sup>1</sup>; Emmanuel Stip<sup>2</sup>; Glenda McQueen<sup>3</sup>; Stéphane Potvin<sup>1</sup>; Miriam Beauchamp<sup>4</sup>; Edouard Kouassi<sup>5</sup>

<sup>1</sup>Department of Psychiatry, Faculty of Medicine, University of Montreal, Institut Universitaire en Santé Mentale de Montréal, Montreal, Canada; <sup>2</sup>Department of Psychiatry, Faculty of Medicine, University of Montreal, Montreal, Canada; <sup>3</sup>Department of Psychiatry, Faculty of Medicine, University of Calgary, Calgary, Canada; <sup>4</sup>Department of Psychology, University of Montreal, Montreal, Canada; <sup>5</sup>Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Canada

### **P 42. SNRI effects on cognitive functioning in recent onset major depression**

Smadar Valérie Tourjman<sup>1,2</sup>; Emmanuel Stip<sup>1</sup>; Glenda McQueen<sup>3</sup>; Miriam Beauchamp<sup>1</sup>; Stéphane Potvin<sup>1,2</sup>; Edouard Kouassi<sup>1,2</sup>

<sup>1</sup>University of Montréal, Montréal, Canada; <sup>2</sup>IUSMM, Montréal, Canada; <sup>3</sup>University of Calgary, Alberta, Canada

### **P 43. Accumbal DNA methylation landscapes of post-traumatic stress disorder susceptibility and resilient point to potential therapeutics**

Gal Warhaftig<sup>1</sup>; Noa Zifman<sup>1</sup>; Chaya-Mushka Sokolik<sup>1</sup>; Renaud Massart<sup>3</sup>; Orshay Gabay<sup>1</sup>; Farida Vaisheva<sup>3</sup>; Moshe Szyf<sup>3,4</sup>; Gal Yadid<sup>1,2</sup>

<sup>1</sup>The Mina & Everard Goodman Faculty of Life Sciences, Ramat-Gan, Israel; <sup>2</sup>The Leslie and Susan Gonda (Goldschmied) Multidisciplinary Brain Research Center, Ramat-Gan, Israel; <sup>3</sup>Department of Pharmacology & Therapeutics, McGill University, Montreal, Canada; <sup>4</sup>Sackler Program for Epigenetics and Psychobiology, McGill University, Montreal, Canada

### **P 44. Changes over time of the diagnostic and therapeutic characteristics of patients of a psychiatric intensive care unit in Austria**

Dietmar Winkler; Alexander Kaltenböck; Richard Frey; Siegfried Kasper; Edda Pjrek



*Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria*

## POSTERS

**P 45. Use of therapeutic sleep deprivation in psychiatric departments in Austria, Germany and Switzerland**

Edda Winkler-Pjrek; Yasmin Al-Resheg; Kasper Siegfried; Dietmar Winkler

*Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria*

**P 46. The feasibility and effectiveness of the web based cognitive behavioral therapy for adolescents with depression**

Ki-Hwan Yook<sup>2</sup>; Hyun Ju Hong<sup>1</sup>

<sup>1</sup>Hallym University Sacred Heart Hospital, Anyang, South Korea; <sup>2</sup>Bundang CHA hospital, Seongnam, South Korea

**P 47. Psychosocial factors associated with suicidal attempt among the adolescents with suicidal ideation**

Bo-Hyun Yoon<sup>1</sup>; Moon-Doo Kim<sup>2</sup>; Kyung-Min Kim<sup>1</sup>

<sup>1</sup>Naju National Hospital, Naju, South Korea; <sup>2</sup>Jeju National University Hospital, Jeju, South Korea

**P 48. Psychosocial factors associated with suicidal ideation among the adolescents with self-harm behavior**

Bo-Hyun Yoon<sup>1</sup>; Moon-Doo Kim<sup>2</sup>; Young-Jun Kwon<sup>3</sup>

<sup>1</sup>Naju National Hospital, Naju, South Korea; <sup>2</sup>Jeju National University Hospital, Jeju, South Korea; <sup>3</sup>Cheonan Suncheonhyang University Hospital, Cheonan, South Korea



## SCIENTIFIC INFORMATION

### Audio-Visual

Equipment for computerized Power Point presentation is provided during the scientific sessions. Power Point presentations, CD-Rom or USB keys can be viewed and tested prior to presentation at the Speakers' Corner and must be handed over to the room technicians at least forty minutes before the beginning of the sessions and collected directly by the speakers immediately after. It is essential for the smooth running of the sessions that all Speakers hand in their presentation in due time.

### European Accreditation

The IFMAD congress has been granted with 12 European CME credits by the European Accreditation Council for Continuing Medical Education (EACCME) and these credits are recognized by the American Medical Association for conversion to AMA PRA Category 1 Credit.



### Certificate of Attendance

A certificate of attendance is provided by e-mail after the Congress.

### Posters

The selected abstracts for poster display (at a maximum height of 100 cm and 90 cm base) are displayed in the Congress area of the NH Hotel from **Thursday, 08 December 2016** to **Saturday, 10 December 2016**. Poster material must be prepared in advance and should be large enough to be viewed at a distance of 2 m. Drawings and charts should be clear and simple. Posters should be attended by the authors themselves, in order to view and discuss them during lunchtime and coffee breaks and a special poster session is scheduled on Saturday from 09.00 to 10.00. The Best Posters will be selected by the Scientific Committee and the Poster Prizes will be announced during the final wrap up at 12.00 on 10 December 2016.



## GENERAL INFORMATION

The “16<sup>th</sup> International Forum on Mood and Anxiety Disorders” is held at the NH Collection Vittorio Veneto from 08-10 December 2016.

### Admission

The participant's name badge is provided at the registration desk. All participants are requested to wear the badge throughout the congress. Only badge holders are admitted to the appropriate sessions and Opening Reception.

### Airport and Transport

#### *How to get to Rome by plane*

There are two main airports in Rome: Rome Fiumicino international airport and Rome Ciampino low cost airport. Both are located outside the city, about 45 min away from the city centre.

#### *How to get to Rome by car*

Going to/Coming from Florence or Naples: A1

Going to/Coming from the East coast : A24

#### *How to get to Rome by train*

Rome is well connected to the main Italian cities as well as less touristy and remote places throughout the country thanks to *Trenitalia's* complete railway network.

Main train stations in Rome:

- *Termini Station*, central hub of public transport in Rome for both buses and Metros (A and B)
- *Tiburtina Station* (Metro B)

### How to get to NH Collection Roma Vittorio Veneto

#### FROM THE AIRPORT

##### *From Fiumicino Airport:*

The hotel is located 30 km from the airport. You may take a train to Stazione Termini. From there, you can take the underground (Line A) and get off at either *Barberini* or *Spagna*. You may also take a taxi.

#### FROM THE TRAIN STATION

NH Collection Roma Vittorio Veneto is located three kilometers from Termini Station. You can take a bus (line 910) and get off Via Puccini, or you can take the underground (Line A) and get off at *Piazza di Spagna*, following signs for Villa Borghese.

Alternatively, you can take a taxi: the station is five minutes from the hotel.





## GENERAL INFORMATION

### Language

The official language of the Congress is English. No simultaneous translation is provided.

### Insurance

The Congress organizers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress. Registration does not include insurance. It is strongly recommended that you take an insurance policy of your choice as you register for the Congress and book your travel.

### Secretariat

The secretariat desk will open on Thursday, 08 December at 12h00 and stay open all through the Congress, Saturday 10 December at 12h30.

### Welcome cocktail

All delegates are cordially invited to attend the Opening Reception which will be held on [Thursday, 08 December](#) at the NH Hotel.



# IFMAD

[www.ifmad.org](http://www.ifmad.org)



**Publi Créations**

74, Bd d'Italie - 98000 Monte-Carlo - Monaco  
Ph. +377 97 97 35 55 - Fax +377 97 97 35 50  
E-mail: [ifmad@publiccreations.com](mailto:ifmad@publiccreations.com)